Prognostic risk factors for rare oncocytic variantin 101 cases of papillary thyroid carcinoma.
Journal
Hellenic journal of nuclear medicine
ISSN: 1790-5427
Titre abrégé: Hell J Nucl Med
Pays: Greece
ID NLM: 101257471
Informations de publication
Date de publication:
Historique:
received:
20
05
2019
accepted:
03
07
2019
pubmed:
6
7
2019
medline:
18
12
2019
entrez:
6
7
2019
Statut:
ppublish
Résumé
Oncocytic variant (OV) is an unusual subtype of papillary thyroid cancer whose histopathologic diagnostic criteria, clinicopathologic features and biological behavior are different and have not been comprehensively studied, characterized in literature. Previous studies present conflicting results upon its prognosis. We investigated demographic and clinicopathologic risk factors affecting its prognosis while presenting our clinical experience. This is a retrospective cohort study reviewing 101 patients of OV from an archive of 4500 well-differentiated thyroid cancer patients treated with iodine-131 ( Seventeen cases (17%) developed metastases/recurrence, 70% of the recurrences occured before 24 months. Four patients (4%) died during the follow-up. Metastatic sites were usually cervical LN, local recurrence in thyroid bed and lungs. Multivariate analysis revealed stage (IV) and TS were the main parameters impacting recurrence/metastases. In the follow-up, isolated cervical LN metastases were found in 41% of metastatic cases, while 12% had sole recurrence in thyroid bed. Eighty eight percent of the metastatic disease included locoregional (cervical) and/or remote LN. The recurrences were associated with initial thyroid masses greater than 3.5cm in diameter. We found that the prognosis of OV is not poor in our series. Stage (IV) and tumor size are the main risk factors in metastatic development.
Identifiants
pubmed: 31273353
pii: s002449911004
doi: 10.1967/s002449911004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM